Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.35 |
| ▸ | XPO1 | O14980 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739594 | 0.78 | ALB (0.38) | NOTUM | |
| SCHEMBL5694237 | 0.76 | EP300 (0.34) | NOTUM | |
| SCHEMBL28449256 | 0.75 | SMN1; SMN2 (0.34) | NOTUM | |
| SCHEMBL4727065 | 0.75 | NOTUM (0.30) | NOTUM | |
| SCHEMBL22468257 | 0.68 | TET2 (0.49) | — | |
| SCHEMBL3825417 | 0.65 | LMNA (0.44) | — | |
| SCHEMBL3826358 | 0.65 | LMNA (0.44) | — | |
| SCHEMBL5694084 | 0.63 | DNMT1 (0.37) | NOTUM | |
| SCHEMBL21186 | 0.63 | NOTUM (0.43) | NOTUM | |
| SCHEMBL27798766 | 0.62 | ALB (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1947092-B1 | Method for producing nucleic acid base having perfluoroalkyl group | TOSOH CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-7884202-B2 | Nucleobases are perfluoroalkylated in a one step process with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound; useful as medicinal drugs, intermediates for medicinal drugs and agricultural chemicals | TOSOH CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20090124796-A1 | Nucleobase Having Perfluoroalkyl Group and Process for Producing the Same | TOSOH CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1947092-A1 | NUCLEIC ACID BASE HAVING PERFLUOROALKYL GROUP AND METHOD FOR PRODUCING THE SAME | Tosoh Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124796-A1 | Nucleobase Having Perfluoroalkyl Group and Process for Producing the Same | PFAS, FPGS, NUDT1 | PIK3CA 2902/4885XPO1 483/4885PIK3CD 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.